CL2007002836A1 - Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer. - Google Patents
Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer.Info
- Publication number
- CL2007002836A1 CL2007002836A1 CL200702836A CL2007002836A CL2007002836A1 CL 2007002836 A1 CL2007002836 A1 CL 2007002836A1 CL 200702836 A CL200702836 A CL 200702836A CL 2007002836 A CL2007002836 A CL 2007002836A CL 2007002836 A1 CL2007002836 A1 CL 2007002836A1
- Authority
- CL
- Chile
- Prior art keywords
- triazine
- pyrimidine
- kinase
- cancer
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82787306P | 2006-10-02 | 2006-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007002836A1 true CL2007002836A1 (es) | 2008-05-23 |
Family
ID=38955203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200702836A CL2007002836A1 (es) | 2006-10-02 | 2007-10-02 | Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer. |
Country Status (22)
Country | Link |
---|---|
US (1) | US8202876B2 (es) |
EP (1) | EP2057146A1 (es) |
JP (1) | JP5153777B2 (es) |
KR (1) | KR101101675B1 (es) |
CN (2) | CN103739595A (es) |
AR (1) | AR063099A1 (es) |
AU (1) | AU2007305016B2 (es) |
BR (1) | BRPI0719797A8 (es) |
CA (1) | CA2663366C (es) |
CL (1) | CL2007002836A1 (es) |
CO (1) | CO6180440A2 (es) |
CR (1) | CR10670A (es) |
EA (1) | EA015751B1 (es) |
IL (1) | IL197724A0 (es) |
MA (1) | MA30772B1 (es) |
MX (1) | MX2009003456A (es) |
NO (1) | NO20091759L (es) |
PE (1) | PE20080828A1 (es) |
SM (1) | SMAP200900020A (es) |
TN (1) | TN2009000105A1 (es) |
TW (1) | TW200823200A (es) |
WO (1) | WO2008042639A1 (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007328981B2 (en) | 2006-12-08 | 2013-07-11 | F. Hoffmann-La Roche Ag | Substituted pyrimidines and their use as JNK modulators |
WO2009012221A1 (en) * | 2007-07-13 | 2009-01-22 | Board Of Regents, The University Of Texas System | Heterocyclic modulators of cannabinoid receptors |
KR101559597B1 (ko) * | 2007-09-28 | 2015-10-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 5―원 헤테로시클릭 화합물 |
WO2009111277A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのraf阻害剤としてのn−(6−アミノピリジン−3−イル)−3−(スルホンアミド)ベンズアミド誘導体 |
TW200940539A (en) * | 2008-02-29 | 2009-10-01 | Array Biopharma Inc | RAF inhibitor compounds and methods of use thereof |
KR20100122505A (ko) * | 2008-02-29 | 2010-11-22 | 어레이 바이오파마 인크. | Raf 저해물질 화합물 및 이들의 이용 방법 |
WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
BRPI0916356B1 (pt) | 2008-07-24 | 2022-08-23 | Nerviano Medical Sciences S.R.L | 3,4-diaril pirazois como inibidores da proteína quinase |
EP2430013B1 (en) * | 2009-05-13 | 2014-10-15 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
AU2012335663B2 (en) | 2011-11-11 | 2015-12-24 | Array Biopharma Inc. | Method of treating a proliferative disease |
WO2013078264A1 (en) | 2011-11-23 | 2013-05-30 | Novartis Ag | Pharmaceutical formulations |
CN106977495B (zh) * | 2012-04-24 | 2020-08-04 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
SG10201610416TA (en) | 2012-06-13 | 2017-01-27 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
ES2900061T3 (es) | 2013-03-12 | 2022-03-15 | Vertex Pharma | Inhibidores de DNA-PK |
SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
AU2014293011A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene |
TR201807411T4 (tr) * | 2013-10-17 | 2018-06-21 | Vertex Pharma | DNA-PK inhibitörleri. |
EP3424920B1 (en) | 2013-10-17 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MX2020004108A (es) | 2015-02-20 | 2022-01-03 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr). |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
WO2016164754A1 (en) * | 2015-04-09 | 2016-10-13 | Eisai R&D Management Co., Ltd. | Fgfr4 inhibitors |
US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10301255B2 (en) * | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US9890163B2 (en) | 2015-10-15 | 2018-02-13 | Princeton Drug Discovery Inc | Inhibitors of protein kinases |
US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
KR20190027814A (ko) | 2016-06-10 | 2019-03-15 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
EP3838897A3 (en) * | 2017-01-20 | 2021-07-07 | Shenzhen TargetRx, Inc. | (hetero)arylamide compound for inhibiting protein kinase activity |
CN108699039B (zh) * | 2017-01-20 | 2019-12-20 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EP3675637A4 (en) | 2017-08-28 | 2021-05-19 | Enanta Pharmaceuticals, Inc. | ANTIVIRAL AGENTS AGAINST HEPATITIS B |
TW201936192A (zh) | 2017-12-06 | 2019-09-16 | 美商因那塔製藥公司 | B 型肝炎抗病毒試劑 |
WO2019113173A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2019141957A1 (en) | 2018-01-19 | 2019-07-25 | Cado Biotechnology Ivs | N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof |
US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
EP3852751A4 (en) | 2018-09-21 | 2022-06-15 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED HETEROCYCLES USEFUL AS ANTIVIRAL AGENTS |
JP2022507724A (ja) | 2018-11-21 | 2022-01-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス剤としての官能化複素環 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
KR20220163285A (ko) | 2021-06-01 | 2022-12-09 | 주식회사 에즈큐리스 | Il-33단백질 저해용 화합물의 스크리닝 방법 및 상기 화합물을 포함하는 알러지성 질환 치료용 약학조성물 |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
WO2023158795A1 (en) * | 2022-02-18 | 2023-08-24 | Accent Therapeutics, Inc. | Inhibitors of rna helicase dhx9 and uses thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE49198T1 (de) * | 1984-05-12 | 1990-01-15 | Fisons Plc | Antiinflammatorische 1,n-diarylpyrazol-3-amine, deren zusammensetzungen und verfahren zu deren herstellung. |
EP1019394A1 (en) | 1997-05-22 | 2000-07-19 | G.D. Searle & Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
US6979686B1 (en) * | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
WO2001030154A2 (de) | 1999-10-25 | 2001-05-03 | Basf Aktiengesellschaft | Pyrazole enthaltende agrochemische zusammensetzungen und ihre verwendung als fungizide flanzenschutzmittel |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
AR042052A1 (es) * | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
AR042067A1 (es) | 2002-11-27 | 2005-06-08 | Bayer Pharmaceuticals Corp | Derivados de anilinopirazol utiles en el tratamiento de la diabetes |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
TW200514776A (en) | 2003-08-06 | 2005-05-01 | Vertex Pharma | Aminotriazole compounds useful as inhibitors of protein kinases |
RU2006128788A (ru) | 2004-01-09 | 2008-02-20 | Новартис АГ (CH) | Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов |
CA2567569A1 (en) * | 2004-05-21 | 2006-01-26 | Banyu Pharmaceutical Co., Ltd. | Selective inhibitors against cdk4 and cdk6 having aminothiazole skeleton |
MY144044A (en) * | 2004-06-10 | 2011-07-29 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
NZ580450A (en) * | 2004-09-17 | 2011-06-30 | Vertex Pharma | Diaminotriazole Compounds Useful as Protein Kinase Inhibitors |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
AU2006247118A1 (en) | 2005-05-20 | 2006-11-23 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
DE102005036126A1 (de) | 2005-07-26 | 2007-02-01 | Carl Zeiss Industrielle Messtechnik Gmbh | Sensormodul für einen Tastkopf eines taktilen Koordinatenmessgerätes |
CA2620425A1 (en) * | 2005-08-31 | 2007-03-08 | Bayer Healthcare Llc | Anilinopyrazole derivatives useful for the treatment of diabetes |
WO2007027855A2 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
EP2024353A2 (en) | 2006-03-16 | 2009-02-18 | Pfizer Products Inc. | Pyrazole compounds |
WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
-
2007
- 2007-09-24 EP EP07814982A patent/EP2057146A1/en not_active Withdrawn
- 2007-09-24 CA CA2663366A patent/CA2663366C/en not_active Expired - Fee Related
- 2007-09-24 AU AU2007305016A patent/AU2007305016B2/en not_active Ceased
- 2007-09-24 BR BRPI0719797A patent/BRPI0719797A8/pt not_active Application Discontinuation
- 2007-09-24 KR KR1020097006724A patent/KR101101675B1/ko not_active IP Right Cessation
- 2007-09-24 JP JP2009531524A patent/JP5153777B2/ja not_active Expired - Fee Related
- 2007-09-24 WO PCT/US2007/079340 patent/WO2008042639A1/en active Search and Examination
- 2007-09-24 MX MX2009003456A patent/MX2009003456A/es active IP Right Grant
- 2007-09-24 CN CN201310581142.7A patent/CN103739595A/zh active Pending
- 2007-09-24 US US12/444,129 patent/US8202876B2/en not_active Expired - Fee Related
- 2007-09-24 CN CNA2007800368577A patent/CN101522661A/zh active Pending
- 2007-09-24 EA EA200970347A patent/EA015751B1/ru not_active IP Right Cessation
- 2007-10-02 TW TW096136908A patent/TW200823200A/zh unknown
- 2007-10-02 AR ARP070104361A patent/AR063099A1/es unknown
- 2007-10-02 PE PE2007001326A patent/PE20080828A1/es not_active Application Discontinuation
- 2007-10-02 CL CL200702836A patent/CL2007002836A1/es unknown
-
2009
- 2009-03-19 IL IL197724A patent/IL197724A0/en unknown
- 2009-03-19 CR CR10670A patent/CR10670A/es not_active Application Discontinuation
- 2009-03-27 SM SM200900020T patent/SMAP200900020A/it unknown
- 2009-03-27 TN TN2009000105A patent/TN2009000105A1/fr unknown
- 2009-04-02 MA MA31753A patent/MA30772B1/fr unknown
- 2009-04-02 CO CO09034040A patent/CO6180440A2/es not_active Application Discontinuation
- 2009-05-04 NO NO20091759A patent/NO20091759L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA015751B1 (ru) | 2011-12-30 |
EA200970347A1 (ru) | 2009-10-30 |
BRPI0719797A2 (pt) | 2017-10-24 |
JP5153777B2 (ja) | 2013-02-27 |
CR10670A (es) | 2009-05-13 |
NO20091759L (no) | 2009-07-01 |
CA2663366A1 (en) | 2008-04-10 |
EP2057146A1 (en) | 2009-05-13 |
AU2007305016B2 (en) | 2011-11-03 |
SMAP200900020A (it) | 2009-05-11 |
BRPI0719797A8 (pt) | 2017-12-26 |
MX2009003456A (es) | 2009-04-14 |
US20100029605A1 (en) | 2010-02-04 |
AR063099A1 (es) | 2008-12-30 |
PE20080828A1 (es) | 2008-08-12 |
MA30772B1 (fr) | 2009-10-01 |
KR20090060322A (ko) | 2009-06-11 |
IL197724A0 (en) | 2009-12-24 |
CA2663366C (en) | 2012-02-07 |
TW200823200A (en) | 2008-06-01 |
JP2010505862A (ja) | 2010-02-25 |
WO2008042639A1 (en) | 2008-04-10 |
CN103739595A (zh) | 2014-04-23 |
CO6180440A2 (es) | 2010-07-19 |
US8202876B2 (en) | 2012-06-19 |
CN101522661A (zh) | 2009-09-02 |
KR101101675B1 (ko) | 2011-12-30 |
TN2009000105A1 (en) | 2010-08-19 |
AU2007305016A1 (en) | 2008-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007002836A1 (es) | Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer. | |
CL2007002316A1 (es) | Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer. | |
CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
CL2007003495A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer. | |
BRPI0818804A2 (pt) | Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. | |
CL2007002017A1 (es) | Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple. | |
CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
CL2007002640A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2007002642A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2007002649A1 (es) | Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes. | |
CL2009000576A1 (es) | Un compuesto {1-etilsulfonil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo o su sal; inhibidor de jak; composicion farmaceutica; y su uso para tratar artritis reumatoide. | |
CL2007003061A1 (es) | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. | |
CL2007003756A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2008000197A1 (es) | Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
CL2008002243A1 (es) | Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
DK3567035T3 (da) | N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer | |
DK2004641T3 (da) | HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner | |
IL197933A (en) | Knaase inhibitors, pharmaceuticals containing them and their uses | |
CL2007003244A1 (es) | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
BRPI0917119A2 (pt) | composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação. | |
DK1945631T3 (da) | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer | |
ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
CL2007000161A1 (es) | Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. |